Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design.
about
A highly conserved neutralizing epitope on group 2 influenza A virusesThe Receptor-Binding Domain of Influenza Virus Hemagglutinin Produced in Escherichia coli Folds into Its Native, Immunogenic StructureCrystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virusBroadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutininCross-Allele Cytotoxic T Lymphocyte Responses against 2009 Pandemic H1N1 Influenza A Virus among HLA-A24 and HLA-A3 Supertype-Positive IndividualsReceptor mimicry by antibody F045–092 facilitates universal binding to the H3 subtype of influenza virusDeterminants of glycan receptor specificity of H2N2 influenza A virus hemagglutininInfluenza pandemic epidemiologic and virologic diversity: reminding ourselves of the possibilities.Immune history shapes specificity of pandemic H1N1 influenza antibody responses.Why does pandemic influenza virus kill?Extreme evolutionary conservation of functionally important regions in H1N1 influenza proteome.Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection.Detection of the influenza A(H1N1)pdm09 virus carrying the K-15E, P83S and Q293H mutations in patients who have undergone bone marrow transplantEpitope mapping of the hemagglutinin molecule of A/(H1N1)pdm09 influenza virus by using monoclonal antibody escape mutants.Pseudotype-based neutralization assays for influenza: a systematic analysis.H1N1: can a pandemic cycle be broken?Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton ratsImpact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferretsCross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions.Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice.Contemporary seasonal influenza A (H1N1) virus infection primes for a more robust response to split inactivated pandemic influenza A (H1N1) Virus vaccination in ferretsPandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus.Glycosylation of the Hemagglutinin Protein of H5N1 Influenza Virus Increases Its Virulence in Mice by Exacerbating the Host Immune Response.Influenza vaccine immunology.Virulence determinants of pandemic influenza viruses.The ability of pandemic influenza virus hemagglutinins to induce lower respiratory pathology is associated with decreased surfactant protein D bindingThe first influenza pandemic of the new millennium.Immunization with 1976 swine H1N1- or 2009 pandemic H1N1-inactivated vaccines protects mice from a lethal 1918 influenza infectionMF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.Pandemic influenza: certain uncertainties.Putative amino acid determinants of the emergence of the 2009 influenza A (H1N1) virus in the human population.A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs.Epidemiological isolation causing variable mortality in Island populations during the 1918-1920 influenza pandemic.Genetic diversity of HA1 domain of hemagglutinin gene of pandemic influenza H1N1pdm09 viruses in New Delhi, India.Seasonal trivalent inactivated influenza vaccine protects against 1918 Spanish influenza virus infection in ferrets.Antibody pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1 virus hemagglutinin drives the emergence of a virus with increased virulence in mice.Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus.H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses.N-linked glycosylation in the hemagglutinin of influenza A viruses.
P2860
Q24630467-DAFFA564-9AFC-458B-95A7-71B05F235576Q27665742-A2BB4628-E638-48F2-8929-C0DA0B29156DQ27666458-BE068D36-EDAF-4611-9108-8104E8E3FCBAQ27671619-A6A6C529-9BBE-43E1-91A6-0F53F315FB6FQ27673689-47BEFFBD-352F-450D-A2E1-123A52DFF1B3Q27683156-09BC1DEC-AD01-408A-8B75-5C12E4CE65CEQ28475970-869B1B7F-FC09-4327-8392-A4323127FBA5Q30226708-17DC91AC-457B-412D-9022-E0CFA819FFDBQ30352126-6DB3BE0A-B63B-4547-95C7-33392D3D6A0CQ30352613-0F3FF978-D635-4F28-97F8-07C47A2888D5Q30356104-CCD6A150-AB0F-49C8-9C74-1B98498C0E86Q30360290-668CFB65-C794-4CBF-9569-36E390649BEEQ30361448-7465FECE-0C04-4A25-84E2-787CDC56732CQ30365694-1038BA5D-B60C-49AD-B464-54390BBE602DQ30374662-7189775A-DC93-4D57-9D23-96D49CC6DEADQ30387826-79DF8670-4B5B-4FA4-B728-B6D6E1E39DCEQ30392931-ED7D8251-E867-4196-BEB3-E85341700916Q30393616-B9CFF423-5259-4DD3-9993-506AF5648C00Q30394072-5AE86DE9-2838-4B10-9273-9DAE19643D61Q30394731-E5FFD0B0-F935-4104-A231-C41F07845AA5Q30395094-B3B167BF-E070-47F4-B3A1-5F64B46805DEQ30395264-D2B0A4D6-9D0B-491D-938D-6EA782628AA9Q30397674-E6E2DA46-D288-4F7D-9E02-70D1E0473BAFQ30398035-172B4406-F874-4FC8-9369-43B6ED10E1D3Q30398168-1AD2E5AA-82E1-4F04-8D62-A18087C0AF5AQ30399889-7F6908E7-BFA9-4167-BBEC-9330313AC0ABQ30401658-59254193-4FED-4A6E-B807-56E1868D3764Q30401669-B321331C-3A2B-42FC-8C3C-EA29DE6C267CQ30403361-F0C2AFCA-AE32-4926-B3FB-5C150C0A82DEQ30404256-2ED99065-01E5-41D4-83F0-87B6632998A9Q30405522-A94304D4-4F7F-4F0D-B958-BF8BAE7F879AQ30406095-3053ED63-CFAA-4C0A-B849-C9A5B77877BAQ30407081-12AC3C56-31C2-442E-BD96-35E36EBCD402Q30411434-1FF8B731-5B20-42A2-A5E6-F7AC442AB901Q30411781-A1D84ADF-F802-43BA-BEB9-D8E009B6173CQ30416288-9E2F1D87-05BD-4A11-8559-E3EA2DFCA4FDQ30417383-CD2DB18B-C2E9-467B-A635-B5036B77733FQ30417675-10CB1865-F284-4918-AAA7-AB0C71E67DEBQ30418834-DFFEA863-E5C5-4427-9214-B690B31CCD32Q30420126-55F19CA7-4B7B-4872-81C1-C71D2A20CFD1
P2860
Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cross-neutralization of 1918 a ...... evolution and vaccine design.
@ast
Cross-neutralization of 1918 a ...... evolution and vaccine design.
@en
type
label
Cross-neutralization of 1918 a ...... evolution and vaccine design.
@ast
Cross-neutralization of 1918 a ...... evolution and vaccine design.
@en
prefLabel
Cross-neutralization of 1918 a ...... evolution and vaccine design.
@ast
Cross-neutralization of 1918 a ...... evolution and vaccine design.
@en
P2093
P2860
P50
P1476
Cross-neutralization of 1918 a ...... evolution and vaccine design.
@en
P2093
Chih-Jen Wei
Jeffrey C Boyington
Kaifan Dai
Katherine V Houser
Wing-Pui Kong
P2860
P304
P356
10.1126/SCITRANSLMED.3000799
P407
P577
2010-03-01T00:00:00Z